Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Unknown 3Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 71UNKNOWN 6OTHER_GOV 6INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 3Metastatic Breast Cancer in the Brain 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × pyrotinib × Clear all
NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Henan Cancer Hospital

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT06475443 2024-06-26

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Henan Cancer Hospital

Phase 2 Not yet recruiting
32 enrolled
Breast

Metastatic Breast Cancer in the Brain

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

Henan Cancer Hospital

Phase 2 Unknown
41 enrolled
Breast

Breast Neoplasms

NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡